Murata Manufacturing: 3-in-1 Soil Sensors Help Maximize Crop Yield and Quality in Smart Agriculture
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has introduced a highly accurate three-in-one soil sensor for data-driven sustainable agriculture. By simultaneously monitoring the electrical conductivity (EC), water content and temperature of the soil, the sensor enables farmers to maximize the yield and quality of crops while minimizing resources such as water and fertilizers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220508005001/en/
[Murata Manufacturing Co., Ltd.] soil sensor (Photo: Business Wire)
The tip of the soil sensor contains a grid of 9 extra-sensitive electrodes that provide consistent measurements of the soil’s EC. Using unique algorithms, these electrodes help measure and compare the EC of pore water, which is the water in between the soil particles, to the volume of the soil’s natural nutrients and added fertilizers. These EC measurements are not affected by soil moisture content, thereby eliminating uncertainty in the soil and contributing to improving crop quality and yield by optimizing fertilizers.
Knowing the water content of the soil also enables the grower to irrigate the soil in an accurate and timely manner, saving water. As well as monitoring soil conditions, the robust and reliable sensor can monitor the water quality of rivers and lakes.
“We have conducted demonstration tests using our soil sensors on a variety of fields and crops to verify their effectiveness,” says Yoshiyuki Oba, developer, Murata. “By using data for management and control, the soil sensors contribute to labor-saving in agricultural work and reduce waste of valuable resources such as water and fertilizer. They also contribute to achieving Sustainable Development Goals (SDGs), such as environmental problems like salt damage and the accompanying food problems caused by global climate change.”
Protected to IP68 equivalent for dust and water, including rust proofing for use in harsh environments, these high-performing and energy-efficient soil sensors can run on three AA batteries for over half a year if the measurement interval is once every 30 minutes. The multi-interface sensors also support UART, RS232E, RS485, SDI-12, and RS485 MODBUS, making them compatible with existing crop management systems.
For more information, please visit: https://www.murata.com/en-global/products/sensor/soil
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220508005001/en/
Contact information
For more information, please contact:
Murata Manufacturing Co., Ltd.
Wakana Nakamura, prsec_mmc@murata.com
Corporate Communications Department
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 09:00:00 EET | Press release
Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies this commitment, offering cloud-native architecture, advanced automation, and AI-driven insights to transform regulatory data into strategic value. By integrating Wolters Kluwer’s F
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 08:21:00 EET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 08:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a patient's quality of life, leading to death if not treated fast enough. Our biosimilars aim to improve access, enable timely care, and ease the financial burden on healthcare systems.”, said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial Division at Samsung Bioepis. “With our proven track records, we’re confident that OBODENCE and XBRYK will deliver meaningful impact on patients and their communities.” OBODENCE, refer
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 23:31:00 EET | Press release
The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. Following Gemini 2.5 Pro, the list of the top five high-performing models included: ChatGPT (O
GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system28.11.2025 13:00:00 EET | Press release
GE HealthCare today announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system,i a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative system represents a leap forward in molecular imaging capabilities and clinical efficiency. As global cancer rates continue to rise – projected to increase 77 percent by 2050ii – the need for advanced imaging solutions has never been greater. The growing prevalence of cancer and emergence of investigational immunotherapies and targeted treatments have accelerated the demand for whole-body PET/CT imaging. GE HealthCare’s new technology is built to meet this need, supporting theranostics and enabling clinicians to visualize, diagnose and monitor disease with impressive precision and speed. “Our commitment to precision health is rooted in innovation that also aim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
